USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AUREOGEN BIOSCIENCES, INC.
Address:
6475 Technology Avenue, Ste C
KALAMAZOO, MI 49009-
Phone:
N/A
URL:
N/A
EIN:
200182587
DUNS:
139133339
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,430,844.00 4
SBIR Phase II $2,460,182.00 2

Award List:

Novel Antifungals by Engineering the AbA NRPS gene

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$162,982.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which is a very potent, fungicidal drug that is currently barred from commercialization due to a… More

Novel Antifungals by Engineering the AbA NRPS gene

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$1,978,701.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides constitute a class of compounds that have made crucial contributions to the treatment of these diseases.… More

A Bacitracin derivative for systemic use

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$381,116.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has not only moved into the general community, but also… More

Generation of novel HCV drugs through engineereing of the cssA gene

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): HCV infections are a prevalent and growing health problem. It is estimated that as many as 2% of the US population, and 2.5% of the population world-wide, are infected by HCV. The disease currently causes 15,000 deaths/ year in US alone, a number that is… More

Generation of novel drugs against drug resistant bacteria through engineering of

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$286,746.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant bacterial infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has not only moved into the general community,… More

Novel Antifungals by Engineering the AbA NRPS gene

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$481,481.00
Agency:
HHS
Principal Investigator:
Ake P. Elhammer – 269-353-3805
Abstract:
DESCRIPTION (provided by applicant): The continuing increase in the number of surgery, transplantation, cancer and other immunocompromized patients, that need treatment for fungal infections, together with the fact that only one new class of antifungal therapeutics has been introduced to the market… More